GALT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
GALT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-01), Galectin Therapeutics's current share price is $3.51. Galectin Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $0.28. Galectin Therapeutics's Cyclically Adjusted PB Ratio for today is 12.54.
The historical rank and industry rank for Galectin Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:
During the past years, Galectin Therapeutics's highest Cyclically Adjusted PB Ratio was 15.06. The lowest was 0.00. And the median was 0.00.
GALT's Cyclically Adjusted PB Ratio is ranked worse thanThe Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Galectin Therapeutics's adjusted book value per share data for the three months ended in Dec. 2023 was $-1.010. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.28 for the trailing ten years ended in Dec. 2023.
The historical data trend for Galectin Therapeutics's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galectin Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Cyclically Adjusted PB Ratio | Get a 7-Day Free Trial | 3.23 | 6.17 | 4.38 | 6.23 | 5.94 |
For the Biotechnology subindustry, Galectin Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Galectin Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Galectin Therapeutics's Cyclically Adjusted PB Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
Galectin Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as
Cyclically Adjusted PB Ratio | = | Share Price | / | Cyclically Adjusted Book per Share |
= | 3.51 | / | 0.28 | |
= | 12.54 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galectin Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:
For example, Galectin Therapeutics's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:
Adj_Book | = | Book Value per Share | / | CPI of Dec. 2023 (Change) | * | Current CPI (Dec. 2023) |
= | -1.01 | / | 129.4194 | * | 129.4194 | |
= | -1.010 |
Current CPI (Dec. 2023) = 129.4194.
Galectin Therapeutics Quarterly Data
Book Value per Share | CPI | Adj_Book | |
201403 | 1.264 | 99.695 | 1.641 |
201406 | 1.142 | 100.560 | 1.470 |
201409 | 1.024 | 100.428 | 1.320 |
201412 | 0.926 | 99.070 | 1.210 |
201503 | 0.897 | 99.621 | 1.165 |
201506 | 0.728 | 100.684 | 0.936 |
201509 | 0.513 | 100.392 | 0.661 |
201512 | 0.607 | 99.792 | 0.787 |
201603 | 0.411 | 100.470 | 0.529 |
201606 | 0.237 | 101.688 | 0.302 |
201609 | 0.125 | 101.861 | 0.159 |
201612 | 0.093 | 101.863 | 0.118 |
201703 | 0.019 | 102.862 | 0.024 |
201706 | -0.090 | 103.349 | -0.113 |
201709 | -0.177 | 104.136 | -0.220 |
201712 | -0.217 | 104.011 | -0.270 |
201803 | -0.168 | 105.290 | -0.207 |
201806 | 0.020 | 106.317 | 0.024 |
201809 | 0.000 | 106.507 | 0.000 |
201812 | -0.050 | 105.998 | -0.061 |
201903 | 0.100 | 107.251 | 0.121 |
201906 | 0.872 | 108.070 | 1.044 |
201909 | 0.833 | 108.329 | 0.995 |
201912 | 0.762 | 108.420 | 0.910 |
202003 | 0.710 | 108.902 | 0.844 |
202006 | 0.609 | 108.767 | 0.725 |
202009 | 0.515 | 109.815 | 0.607 |
202012 | 0.384 | 109.897 | 0.452 |
202103 | 0.280 | 111.754 | 0.324 |
202106 | 0.251 | 114.631 | 0.283 |
202109 | 0.118 | 115.734 | 0.132 |
202112 | 0.006 | 117.630 | 0.007 |
202203 | -0.142 | 121.301 | -0.152 |
202206 | -0.294 | 125.017 | -0.304 |
202209 | -0.413 | 125.227 | -0.427 |
202212 | -0.579 | 125.222 | -0.598 |
202303 | -0.753 | 127.348 | -0.765 |
202306 | -0.896 | 128.729 | -0.901 |
202309 | -0.859 | 129.860 | -0.856 |
202312 | -1.010 | 129.419 | -1.010 |
Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Thank you for viewing the detailed overview of Galectin Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Kary Eldred | director | 2121 RINGWOOD AVENUE, SAN JOSE CA 95131 |
Kevin D Freeman | director | 712 LAKEWAY DRIVE, KELLER TX 76248 |
Zordani Richard A. Jr. | director | 467 N. COUNTRY RIDGE CT., LAKE ZURICH IL 60047 |
10x Fund, L.p. | 10 percent owner | 1099 FOREST LAKE TERRACE, NICEVILLE FL 32578 |
Elissa J. Schwartz | director | 235 SW CHURCH ST., PULLMAN WA 99163 |
Gilbert F Amelio | director | 5835 STRASBOURG COURT, ---, RENO NV 89511 |
Richard E Uihlein | director, 10 percent owner | 12575 ULINE DRIVE, PLEASANT PRAIRIE WI 53158 |
Pol F Boudes | officer: Chief Medical Officer | C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560 |
Joel Lewis | director | 12575 ULINE DRIVE, PLEASANT PRAIRIE WI 53158 |
Gilbert S Omenn | director | AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799 |
Harold H. Shlevin | director, officer: Chief Executive Officer | C/O GALECTIN THERAPEUTICS, INC., 4690 PEACHTREE INDUSTRIAL BLVD, STE. 240, NORCROSS GA 30071 |
Jack W Callicutt | officer: Chief Financial Officer | 75 FIFTH STREET NW STE. 313, ATLANTA GA 30308 |
Marc Rubin | director | C/O TITAN PHARMACEUTICALS, INC., 400 OYSTER POINT BLVD., STE 505, SAN FRANCISCO CA 94080 |
James C Czirr | director | 4908 SOUTH ASHTON COURT, SPOKANE WA 99223 |
Peter G Traber | director, officer: President and CEO | 430 THAMER LANE, HOUSTON TX 77025 |
From GuruFocus
By Marketwired • 09-11-2023
By Marketwired • 08-14-2023
By sperokesalga sperokesalga • 04-18-2023
By sperokesalga sperokesalga • 05-15-2023
By GuruFocus Research • 11-13-2023
By PurpleRose PurpleRose • 08-15-2022
By sperokesalga sperokesalga • 03-30-2023
By Marketwired • 09-07-2023
By Value_Insider Value_Insider • 11-29-2022
By Marketwired • 10-12-2023